Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic and safety study of sirolimus or everolimus combined with HCV direct acting antiviral agents (ombitasvir, paritaprevir/r and dasabuvir) in healthy subjects

Next Previous
Trial Profile

Pharmacokinetic and safety study of sirolimus or everolimus combined with HCV direct acting antiviral agents (ombitasvir, paritaprevir/r and dasabuvir) in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 02 Apr 2017 New trial record
  • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top